MX2022008130A - Derivado de insulina. - Google Patents

Derivado de insulina.

Info

Publication number
MX2022008130A
MX2022008130A MX2022008130A MX2022008130A MX2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A
Authority
MX
Mexico
Prior art keywords
insulin
pharmaceutical composition
acylated insulin
pharmaceutical formulation
insulin derivative
Prior art date
Application number
MX2022008130A
Other languages
English (en)
Spanish (es)
Inventor
Wei Chen
Zhongru Gan
Yining Zhang
Fangkai Xue
Lingyu Cai
Jianghong Niu
Bin Mu
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan & Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of MX2022008130A publication Critical patent/MX2022008130A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022008130A 2019-12-30 2020-12-29 Derivado de insulina. MX2022008130A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911398378 2019-12-30
CN202011057926 2020-09-29
PCT/CN2020/141023 WO2021136296A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (1)

Publication Number Publication Date
MX2022008130A true MX2022008130A (es) 2022-10-03

Family

ID=76687317

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022008130A MX2022008130A (es) 2019-12-30 2020-12-29 Derivado de insulina.
MX2022008174A MX2022008174A (es) 2019-12-30 2020-12-29 Derivado de insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008174A MX2022008174A (es) 2019-12-30 2020-12-29 Derivado de insulina.

Country Status (10)

Country Link
US (5) US20240025957A1 (cg-RX-API-DMAC7.html)
EP (3) EP4086279A4 (cg-RX-API-DMAC7.html)
JP (3) JP2023510219A (cg-RX-API-DMAC7.html)
KR (2) KR20220121833A (cg-RX-API-DMAC7.html)
CN (12) CN118754967A (cg-RX-API-DMAC7.html)
AU (2) AU2020417892B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022013009A2 (cg-RX-API-DMAC7.html)
CA (2) CA3166495A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022008130A (cg-RX-API-DMAC7.html)
WO (3) WO2021136302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3217734A1 (en) * 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
CN117586376A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效胰岛素化合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
JP2026517987A (ja) * 2023-05-24 2026-06-02 ザ ユナイテッド バイオテクノロジー(ヘンチン)シーオー.,エルティーディー. インスリン誘導体およびその使用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
AU2024358560A1 (en) * 2023-10-09 2026-05-14 Gan & Lee Pharmaceuticals Co., Ltd. Glp -1 peptide composition and use thereof
WO2025098457A1 (zh) 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN122555570A (zh) * 2023-11-08 2026-08-11 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物
CN120887973A (zh) * 2024-06-13 2025-11-04 惠升生物制药股份有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
JP5202338B2 (ja) * 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102149411A (zh) * 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
EP2720711A1 (en) * 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
JP6737793B2 (ja) * 2015-01-29 2020-08-12 ノヴォ ノルディスク アー/エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341991B1 (en) * 2015-08-27 2020-07-08 Haldor Topsøe A/S High tap density lithium positive electrode active material, intermediate and process of preparation
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素

Also Published As

Publication number Publication date
CN114901681B (zh) 2024-04-09
WO2021136302A1 (zh) 2021-07-08
CA3166494A1 (en) 2021-07-08
CN118598978A (zh) 2024-09-06
US20250032589A1 (en) 2025-01-30
EP4086279A4 (en) 2024-08-07
US12576136B2 (en) 2026-03-17
CN118894922A (zh) 2024-11-05
BR112022013150A2 (pt) 2023-02-28
EP4086278A4 (en) 2024-08-07
WO2021136296A1 (zh) 2021-07-08
WO2021136293A1 (zh) 2021-07-08
JP2023510219A (ja) 2023-03-13
US20250228919A1 (en) 2025-07-17
CN114901681A (zh) 2022-08-12
CN114901683A (zh) 2022-08-12
KR20220119730A (ko) 2022-08-30
EP4086280A1 (en) 2022-11-09
EP4086279A1 (en) 2022-11-09
EP4086278A1 (en) 2022-11-09
CN114901682A (zh) 2022-08-12
CN118420744A (zh) 2024-08-02
CA3166495A1 (en) 2021-07-08
MX2022008174A (es) 2022-08-02
US20230126068A1 (en) 2023-04-27
US20240239862A1 (en) 2024-07-18
CN118754967A (zh) 2024-10-11
BR112022013009A2 (pt) 2022-09-06
EP4086280A4 (en) 2024-05-29
CN118480114A (zh) 2024-08-13
KR20220121833A (ko) 2022-09-01
US20240025957A1 (en) 2024-01-25
CN118666989A (zh) 2024-09-20
CN114901683B (zh) 2024-09-13
CN118772259A (zh) 2024-10-15
AU2020417892A1 (en) 2022-08-25
CN114901682B (zh) 2024-04-16
AU2020418205B2 (en) 2026-07-30
JP2025161829A (ja) 2025-10-24
CN118420743A (zh) 2024-08-02
AU2020417892B2 (en) 2026-07-09
CN118206632A (zh) 2024-06-18
AU2020418205A1 (en) 2022-08-04
JP2023510206A (ja) 2023-03-13

Similar Documents

Publication Publication Date Title
MX2022008174A (es) Derivado de insulina.
CY1123597T1 (el) Σκευασματα ινσουλινης για γρηγορη προσληψη
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
MX2021009475A (es) Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX378856B (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
NI201200086A (es) Composición farmacéutica que comprende un agonista de glp - 1 y metionina
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
EA201990501A1 (ru) Фармацевтическая композиция
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
MX2015006998A (es) Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
MX2019003099A (es) Composicion farmaceutica.
TN2021000076A1 (en) Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
ZA201902049B (en) Pharmaceutical composition
MX387725B (es) Composición farmacéutica.
CO2022004978A2 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2021007124A (es) Composicion farmaceutica que incluye insulina y glucagon.
CL2022000617A1 (es) Formulaciones de insulina y glucagón inyectables por vía subcutánea y métodos de administración